EP1656128A4 - Treatment for acne vulgaris and method of use - Google Patents

Treatment for acne vulgaris and method of use

Info

Publication number
EP1656128A4
EP1656128A4 EP03818329A EP03818329A EP1656128A4 EP 1656128 A4 EP1656128 A4 EP 1656128A4 EP 03818329 A EP03818329 A EP 03818329A EP 03818329 A EP03818329 A EP 03818329A EP 1656128 A4 EP1656128 A4 EP 1656128A4
Authority
EP
European Patent Office
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03818329A
Other languages
German (de)
French (fr)
Other versions
EP1656128A1 (en
Inventor
William M Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William M Yarbrough Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1656128A1 publication Critical patent/EP1656128A1/en
Publication of EP1656128A4 publication Critical patent/EP1656128A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included ⁇ . BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as “blackheads", or closed, commonly referred to as “whiteheads”. As a group, non- inflammatory papules are called comedones.
  • a topical treatment for acne 5 vulgaris a topical treatment for acne 5 vulgaris.
  • a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area.
  • the composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS").
  • SLS Sodium Lauroyl Sarcosinate
  • An inert 9 scrubbing agent such as polyethylene beads, can also be included to the formula.
  • Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
  • Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules.
  • the ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed.
  • the cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3
  • an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A treatment for Acne Vulgaris is provided for in a topical treatment. According to the invention, a method is provided for applying composition substances to the infected area, working the composition into the infected area, and removing the composition from the infected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarcosinate. Alternatively, the ethoxylate can be exchanged for a methoxylate or a propoxylate. An inert scrubbing agent, such as polyethylene beads, can also be included. Acetylated lanolin alcohol, sodium Lauroyl Sarcosinate, EDTA, a foam stabilizer, and water can also be added to the composition to assist performance.

Description

Invention: Treatment for Acne Vulgaris and Method of Use Inventor: William M. Yarbrough I. FIELD OF THE INVENTION The present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included π. BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as "blackheads", or closed, commonly referred to as "whiteheads". As a group, non- inflammatory papules are called comedones. Closed comedones can lead to inflammatory nodules, papules, and pustules. Severe cases of acne vulgaris can lead to scars characterized by pitting. It is believed that acne results from partial rupture of a partially inflamed follicle. The follicle then spills its components, thereby resulting in the development of a perifollicular inflammatory process. Generally, fresh lesions are sterile, but later gram- positive diptheroids are present. Many times the skin will have a greasy look to it; this is probably due, at least in part, to the release of fatty acids during lipolysis induced by P. acnes. Acne can be a serious problem. It generally manifests itself during adolescence and spontaneously resolves in the late teens or early twenties; although for some, it can be a life long problem. Mild to moderate acne is most often treated with topical agents. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 More severe cases are treated with incision and drainage of lesions, ultraviolet light 2 therapy, and systemic antibiotics. 3 The prior art is replete with compositions for use in the treatment of acne. 4 Topical agents, such as benzoyl peroxide, are thought to decrease bacteria and are often 5 used in the treatment of acne. These treatments are found in many forms, lotions, gels, 6 pads, etc. and are generally available over the counter. Retinol in various forms has been 7 more recently proposed by various Inventors. There are also many soaps used in the 8 treatment of acne. A major shortcoming of most of the prior art is that they often do not 9 penetrate sufficiently and they leave the skin dry. 10 H. OBJECTS OF THE INVENTION 11 It is an object of the present invention to provide a treatment that helps to alleviate 12 the local signs and symptoms caused by acne vulgaris. 13 It is a further object of the present invention to provide a method of use of the 14 present inventive treatment. 15 It is yet another object of the present invention to provide a treatment that 16 includes at least a first nonyl phenyl ethoxylate and sodium lauroyl sarcosinate to which a 17 second nonyl phenyl ethoxylate, acetylated lanolin alcohol, EDTA, a foam stabilizer, 18 water, and inert polyethylene granules can be added without altering the effectiveness of 19 the treatment. 20 It is a yet further object of the present invention to provide a treatment that is safe 21 to use. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 It is yet another object of the present invention to provide such treatment that is 2 topical, can be purchased over the counter, and is economical. 3 TV. SUMMARY OF THE INVENTION 4 The above objects of the invention are provided for in a topical treatment for acne 5 vulgaris. According to the invention, a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area. The composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS"). An inert 9 scrubbing agent, such as polyethylene beads, can also be included to the formula. 10 Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance. 12 Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules. The ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed. For 18 example, if the functional groups at the ends of the individual molecules are exchanged 19 for other functional groups that retain the ability to undergo an emulsion polymerization, 20 then the effectiveness of the compound is also retained. Another example is to change the 21 ethoxylate to a methoxylate or propoxylate. These formations would still retain a similar INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 polarity but would be different compounds with different characteristics. Yet another 2 example would be to exchange triply bound Nitrogen with a doubly bound or perhaps 3 Nitrogen with 4 Carbons bound to it. 4 V. DETAILED DESCRIPTION OF THE INVENTION 5 Chemical analysis and research has revealed that two of the component parts of 6 the inventive composition are principally involved in its effectiveness as an acne 7 treatment: an ethoxylate and Sodium Lauroyl Sarcosinate ("SLS"). The ethoxylate is 8 preferably a nonyl phenol ethoxylate. 9 The Inventor has also found, however, that other formulas that keep the polarity 10 similar to that of the inventive formula will also work. To keep the polarity similar, it is 11 necessary for the compound to have similar characteristics, such as Carbon chains, 12 carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and 13 appropriate functional groups at the ends of the individual molecules. The ideal 14 substitute chemicals would have all of the characteristics mentioned above, but it is not 15 necessary to have every one of those as listed. For example, if the functional groups at the 16 ends of the individual molecules are exchanged for other functional groups that retain the 17 ability to undergo an emulsion polymerization, then the effectiveness of the compound is 18 also retained. Another example is to change the ethoxylate to a methoxylate or 19 propoxylate. These formations would still retain a similar polarity but would be different 20 compounds with different characteristics. Yet another example would be to exchange INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 triply bound Nitrogen with a doubly bound or perhaps Nitrogen with 4 Carbons bound to 2 it. 3 The inventor has also discovered that the addition of an inert scrubbing agent 4 improves the action of the inventive composition. The beads should be large enough to 5 be effective but not so large as to cause abrasions. The inventor suggests beads in the 6 range of 5 to 50 microns with an average size being approximately 25 microns or 50 7 mesh. 8 To make the inventive composition, an exact ratio of ethoxylate to SLS is not 9 critical. The only requirement is that the ethoxylate is completely reacted with the SLS, 10 creating a polymer. This will vary with the ethoxylate used, but the Inventor has 11 determined that a ratio of ethoxylate-to- SLS of 1.5:2 is preferred. The amount by weight 12 of polyethylene beads can vary according to the grittiness desired. The Inventor has 13 found that a formula of ethoxylate: SLS .polyethylene of 40:20:40 is preferred but that 14 formulas of other concentrations are useful. Thus, for production purposes, formulas 15 having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by 16 weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the 17 formula is not restricted to these ranges, which ranges are presented for example purposes 18 only. 19 Also, a cutting agent that does not chemically react with the composition may be 20 added. The cutting agent makes the overall composition flow more easily, thereby INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 enabling more packaging options, such as tubes. The cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3 In use, an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Claims

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 CLAIMS 2 I CLAIM: 3 1. A Treatment for Acne Vulgaris comprising sodium lauroyl sarcosinate and a 4 nonyl phenyl ethoxylate in combination. 5 6 2. The treatment for Acne Vulgaris of Claim 1 further including a second nonyl 7 phenyl ethoxylate. 8 9 3. The treatment for Acne Vulgaris of Claim 1 further including acetylated lanolin 10 alcohol. 11 12 4. The treatment for Acne Vulgaris of Claim 1 further including polyethylene 13 granules. 14 15 5. The treatment for Acne Vulgaris of Claim 1 further including water. 16 17 6. The treatment for Acne Vulgaris of Claim 1 further including 18 ethylenediaminetetraacetic acid. 19 20 7. The treatment for Acne Vulgaris of Claim 1 further including a foam stabilizing 21 agent. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 2 8. The treatment for Acne Vulgaris of Claim 1 further including a cutting agent. 3 4 9. The cutting agent of Claim 8 being selected from the group of aqueous based 5 solutions and oil based solutions. 6 7 10. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged 8 for a methoxylate. 9 10 11. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged 11 for a propoxylate. 12 13 12. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl 14 sarcosinate, and scrubbing means. 15 16 13. The treatment for Acne Vulgaris of Claim 12 wherein the scrubbing mean is 17 polyethylene beads. 18 19 14. The treatment for Acne Vulgaris of Claim 12 further including a cutting agent. 20 INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 15. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged 2 for a methoxylate. 3 4 16. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged 5 for a propoxylate. 6 7 17. A treatment for Acne Vulgaris comprising: a first ethoxylate, a second ethoxylate, 8 acetylated lanolin alcohol, sodium lauroyl sarcosinate, EDTA, a foam stabilizer, water, 9 and inert polyethylene granules. 10 11 18. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is 12 exchanged for a methoxylate. 13 14 19. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is 15 exchanged for a propoxylate. 16 17 20. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl 18 sarcosinate, and EDTA. 19 20 21. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged 21 for a methoxylate. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 2 22. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged 3 for a propoxylate. 4 5 23. A method for treating Acne Vulgaris comprising the steps of: 6 preparing a composition comprising an ethoxylate and sodium lauroyl 7 sarcosinate; 8 applying the composition to an infected area; 9 permitting the composition to remain on the infected area a sufficient 10 amount of time to enable the composition of matter to cause an effect; and, 11 removing the composition from the infected area. 12 13 24. The method of Claim 23 wherein preparing the composition further includes 14 adding second ethoxylate. 15 16 25. The method of Claim 23 wherein preparing the composition further includes 17 adding acetylated lanolin alcohol. 18 19 26. The method of Claim 23 wherein preparing the composition further includes 20 adding acetylated polyethylene granules. 21 INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 27. The method of Claim 23 wherein preparing the composition further includes 2 adding water. 3 4 28. The method of Claim 23 wherein preparing the composition further includes 5 EDTA. 6 7 29. The method of Claim 23 wherein preparing the composition further includes a 8 foam stabilizer. 9 10 30. The method of Claim 23 further including the step of adding a thinning agent to 11 the composition. 12 13 31. The method of Claim 23 wherein the ethoxylate is exchanged for a methoxylate. 14 15 32. The method of Claim 23 wherein the ethoxylate is exchanged for a propoxylate.
EP03818329A 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use Withdrawn EP1656128A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Publications (2)

Publication Number Publication Date
EP1656128A1 EP1656128A1 (en) 2006-05-17
EP1656128A4 true EP1656128A4 (en) 2007-02-28

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03818329A Withdrawn EP1656128A4 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Country Status (5)

Country Link
EP (1) EP1656128A4 (en)
JP (1) JP2007521234A (en)
AU (1) AU2003264053A1 (en)
CA (1) CA2535550A1 (en)
WO (1) WO2005018629A1 (en)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
FR2923383B1 (en) * 2007-11-08 2010-03-19 Oreal USE OF AN N-ACYLATED SARCOSINATE AS A MICROBIAL ANTI-ADHESION AGENT.
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
HUE042053T2 (en) 2008-06-05 2019-06-28 Ablynx Nv Amino acid sequences against viral envelope proteins and polypeptides containing them for treating viral diseases
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2364328A2 (en) 2008-12-10 2011-09-14 Ablynx NV Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
HUE053480T2 (en) 2009-04-30 2021-06-28 Ablynx Nv Method for the production of domain antibodies
KR101852204B1 (en) 2009-06-05 2018-04-26 아블린쓰 엔.브이. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
LT2805731T (en) 2009-09-03 2019-02-11 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
HRP20251657T1 (en) 2009-12-14 2026-02-13 Ablynx N.V. SINGLE VARIABLE DOMAIN IMMUNOGLOBULIN ANTIBODIES AGAINST OX40L, CONSTRUCTS AND THEIR THERAPEUTIC USE
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
ES2738114T3 (en) 2010-02-11 2020-01-20 Ablynx Nv Methods and compositions for aerosol preparation
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
MX2012013490A (en) 2010-05-20 2013-01-29 Ablynx Nv BIOLOGICAL MATERIALS RELATED TO HER3.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
ES2660895T3 (en) 2010-10-29 2018-03-26 Ablynx N.V. Method for the production of individual variable domains of immunoglobulin
PL2635607T3 (en) 2010-11-05 2020-05-18 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EA037063B1 (en) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2 binding polypeptides
EP2691418A1 (en) 2011-03-28 2014-02-05 Ablynx N.V. Bispecific anti-cxcr7 immunoglobulin single variable domains
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
KR102072250B1 (en) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Inhibition of bone resorption with rankl binding peptides
JP2014525736A (en) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． Immunoglobulin single variable domain for IgE
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
PL2773671T3 (en) 2011-11-04 2022-01-24 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
JP6351572B2 (en) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Heteromultimeric constructs of immunoglobulin heavy chains with mutations in the Fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2994530A4 (en) 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2015329935B2 (en) 2014-10-10 2019-09-19 Ablynx N.V. Inhalation device for use in aerosol therapy of respiratory diseases
CA2963037A1 (en) 2014-10-10 2016-04-14 Vectura Gmbh Treatment of rsv infection
CN107406497A (en) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 The nano antibody dimer of cysteine connection
CN108473561B (en) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 Polypeptide inhibiting CD40L
SE543153C2 (en) 2016-05-19 2020-10-13 Biocool Ab Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment
EP3468530A4 (en) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. NON-COMEDOGENOUS HAIR AND SCALP CARE FORMULATIONS AND METHOD OF USE
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
IL317416A (en) 2016-11-16 2025-02-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
BR112019017853A2 (en) 2017-02-28 2021-04-27 Vib Vzw MEANS AND METHODS FOR ORAL RELEASE OF PROTEIN
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CN111032695B (en) 2017-06-02 2024-06-25 默克专利股份有限公司 ADAMTS-binding immunoglobulin
MX2019014504A (en) 2017-06-02 2020-07-20 Merck Patent Gmbh AGRECAN-BINDING IMMUNOGLOBULINS.
CN110997001A (en) 2017-06-02 2020-04-10 默克专利股份有限公司 MMP13 binding to immunoglobulins
MX2019014397A (en) 2017-06-02 2020-02-10 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan.
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP4635987A3 (en) 2017-10-31 2026-01-14 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
CN111670202A (en) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 Methods of treating initial episodes of TTP with immunoglobulin single variable domains
EP3758742A1 (en) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
JP7390729B2 (en) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Wnt signaling agonist molecules
EP4378485A3 (en) 2019-03-08 2024-08-28 LinXis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
CN113527488B (en) 2020-04-22 2026-04-17 迈威(上海)生物科技股份有限公司 A monovariable domain antibody targeting human programmed death-ligand 1 (PD-L1) and its derivatives
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022060223A1 (en) 2020-09-16 2022-03-24 Linxis B.V. Internalizing binding molecules
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4294407A1 (en) 2021-02-17 2023-12-27 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
CN117321076A (en) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 Single domain antibodies that neutralize SARS-CoV-2
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof
AR129560A1 (en) 2022-06-08 2024-09-04 Tidal Therapeutics Inc IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF THEIR SYNTHESIS AND USE
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
JP2025523630A (en) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ Blood-cerebrospinal fluid barrier crossing antibodies
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
KR20250124145A (en) 2022-12-21 2025-08-19 젠자임 코포레이션 anti-PD-1×4-1BB binding protein
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
EP4655323A1 (en) 2023-01-27 2025-12-03 Vrije Universiteit Brussel Cd8b-binding polypeptides
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
CN121511260A (en) 2023-05-11 2026-02-10 非营利性组织佛兰芒综合大学生物技术研究所 SLC4A4/NBCe1 inhibitors
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025093509A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system for measuring parameters of a drug delivery device and method for localizing the electronic system
WO2025093510A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system
WO2025093512A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system
WO2025093511A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system for a drug delivery device
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025157888A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module with transmission component
WO2025157891A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157890A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157886A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157893A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157887A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising electrically conductive elements providing a switch
WO2025157892A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157885A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
EP4591905A1 (en) 2024-01-24 2025-07-30 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157884A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a microswitch
US12138428B1 (en) 2024-01-24 2024-11-12 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157883A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module with a mechanical coupling element
WO2025172500A1 (en) 2024-02-14 2025-08-21 Sanofi Method for determining the dose capturing accuracy
WO2025181125A1 (en) 2024-02-28 2025-09-04 Sanofi Attachment mechanism, module and assembly herewith
WO2025181154A1 (en) 2024-02-28 2025-09-04 Sanofi Attachment mechanism, module and assembly herewith
EP4609896B1 (en) 2024-02-28 2026-04-29 Sanofi Attachment mechanism, module and assembly herewith
US12357764B1 (en) 2024-02-28 2025-07-15 Sanofi Attachment mechanism, module and assembly herewith
EP4609897B1 (en) 2024-02-28 2026-02-18 Sanofi Attachment mechanism, module and assembly herewith
US12144969B1 (en) 2024-02-28 2024-11-19 Sanofi Attachment mechanism, module and assembly herewith
WO2025196180A1 (en) 2024-03-21 2025-09-25 Sanofi Electronic system
WO2025207599A1 (en) 2024-03-26 2025-10-02 Genzyme Corporation Medicament container for lyophilizable medicament
WO2025207603A1 (en) 2024-03-26 2025-10-02 Genzyme Corporation Medicament container for lyophilizable medicament
EP4623963B1 (en) 2024-03-28 2026-04-22 Sanofi Electronic add-on module and assembly of an electronic add-on mod-ule and a drug delivery device
EP4623956B1 (en) 2024-03-28 2026-05-13 Sanofi Attachment mechanism, module and assembly herewith
US12239828B1 (en) 2024-03-28 2025-03-04 Sanofi Attachment mechanism, module and assembly herewith
WO2025202308A1 (en) 2024-03-28 2025-10-02 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025212968A1 (en) 2024-04-05 2025-10-09 Genzyme Corporation Fluid guide system usable for drug handling, e.g. for reconstitution, corresponding medical device, method and computer related items
WO2025212970A1 (en) 2024-04-05 2025-10-09 Genzyme Corporation Multi-vial adapters for reconstituting or diluting lyophilized or concentrated drug products
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025221759A1 (en) 2024-04-17 2025-10-23 Genzyme Corporation Reconstituable drug formulation, medicament container and method of preparing an injectable medicament
WO2025221761A2 (en) 2024-04-17 2025-10-23 Genzyme Corporation Medicament container and kit for reconstituting a lyophilized medicament
WO2025222101A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Reconstitution kit for preparing an injectable liquid medicament, system for preparing an injectable liquid medicament, methods of preparing an injectable liquid medicament
WO2025222112A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Adapter for a medicament container, preparation kit comprising an adapter and a medicament container and method of preparing an injectable liquid medicament
WO2025221983A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Medicament container, set of medicament containers, kit comprising a medicament container and an adapter and methods of preparing an injectable liquid medicament
WO2025229160A1 (en) 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof
EP4647095B1 (en) 2024-05-10 2026-05-06 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025233436A1 (en) 2024-05-10 2025-11-13 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025233480A1 (en) 2024-05-10 2025-11-13 Sanofi Electronic system
US12186538B1 (en) 2024-05-10 2025-01-07 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025237857A1 (en) 2024-05-13 2025-11-20 Sanofi Electronic circuit for monitoring operation of an injection device and method of recording operation of an injection device
US12357539B1 (en) 2024-05-16 2025-07-15 Genzyme Corporation Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
US12213944B1 (en) 2024-05-16 2025-02-04 Genzyme Corporation Fluid transfer device
US12171719B1 (en) 2024-05-16 2024-12-24 Genzyme Corporation Fluid transfer device
US12226371B1 (en) 2024-05-16 2025-02-18 Genzyme Corporation Fluid transfer device
WO2025242704A1 (en) 2024-05-22 2025-11-27 Sanofi Electronic module, assembly of an electronic module and a drug delivery device and method for switching an electronic module
US20250360263A1 (en) 2024-05-24 2025-11-27 Genzyme Corporation Drug delivery device for delivering at least one drug, optionally at least one reconstituted drug, medical device and medical system
WO2025247953A1 (en) 2024-05-31 2025-12-04 Sanofi Wearable electronic device and method of monitoring use of an injection device
WO2025247955A1 (en) 2024-05-31 2025-12-04 Sanofi Wearable electronic device and method of monitoring use of an injection device
US12329940B1 (en) 2024-06-06 2025-06-17 Sanofi Drug delivery device, assembly for a drug delivery device, method for assembling the drug delivery device and use of the drug delivery device
WO2025252454A1 (en) 2024-06-06 2025-12-11 Sanofi Drug delivery device, assembly for a drug delivery device, method for assembling the drug delivery device and use of the drug delivery device
WO2025257207A1 (en) 2024-06-11 2025-12-18 Sanofi Method for improving data accuracy of dose size data, a user equipment and a mobile application
WO2025257274A1 (en) 2024-06-12 2025-12-18 Sanofi Syringe masking cover and combination of such a syringe masking cover with a syringe
WO2025264592A1 (en) 2024-06-17 2025-12-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026027592A1 (en) 2024-08-01 2026-02-05 Sanofi Cap removal aid and assembly therewith
WO2026027628A1 (en) 2024-08-01 2026-02-05 Sanofi Drug delivery device usage detection
WO2026043981A1 (en) 2024-08-21 2026-02-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026043974A1 (en) 2024-08-21 2026-02-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026047140A1 (en) 2024-09-02 2026-03-05 Sanofi Drug delivery device and methods of assembling and use thereof
WO2026047142A1 (en) 2024-09-02 2026-03-05 Sanofi Drive subassembly for a drug delivery device, drug delivery device, and methods of assembling and use thereof
WO2026047141A1 (en) 2024-09-02 2026-03-05 Sanofi Drug subassembly for a drug delivery device, drug delivery device, and methods of assembling and use thereof
WO2026062214A1 (en) 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026077997A1 (en) 2024-10-08 2026-04-16 Sanofi Reusable cap for a drug delivery device and arrangement comprising the reusable cap
WO2026080873A1 (en) 2024-10-11 2026-04-16 Genzyme Corporation Adapter and injection kit
EP4730342A1 (en) 2024-10-18 2026-04-22 Sanofi Method, system and apparatus for estimating titer for immunoglobulin single variable domain molecules
WO2026087207A1 (en) 2024-10-25 2026-04-30 Sanofi Training structure prediction neural networks using active learning
US12357538B1 (en) 2024-11-25 2025-07-15 Genzyme Corporation Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
US12377023B1 (en) 2024-12-02 2025-08-05 Genzyme Corporation Fluid transfer device
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device
US12539367B1 (en) 2025-02-26 2026-02-03 Genzyme Corporation Medicament delivery device
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005018629A1 *

Also Published As

Publication number Publication date
JP2007521234A (en) 2007-08-02
WO2005018629A1 (en) 2005-03-03
AU2003264053A1 (en) 2005-03-10
CA2535550A1 (en) 2005-03-03
EP1656128A1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
WO2005018629A1 (en) Treatment for acne vulgaris and method of use
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
US4514385A (en) Anti-acne compositions
AU2012242682B2 (en) Sodium hypochlorite-based body wash compositions
JP3434435B2 (en) Hair cosmetic composition having dandruff inhibitory effect
US6197317B1 (en) Composition and method for the treatment of skin
MX2007005444A (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound.
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
MXPA06001668A (en) Treatment for acne vulgaris and method of use
JP2001504153A (en) Germicidal soap bar
CA2614846A1 (en) Acne treatment
JP2668853B2 (en) Kitchen detergent
WO2000069403A1 (en) Alpha amino acid composition and method for the treatment of skin
JP2001079568A (en) Dechlorinating agent
CN111743793A (en) Hand sanitizer and preparation method thereof
JP2004131503A (en) Beta-hydroxy acids with enhanced solubility and high-efficiency skin exfoliants formulated with them
JPH0324443B2 (en)
JP3293692B2 (en) Fungicide composition for sandbox containing iodine
Andersen et al. Occupational irritant contact folliculitis associated with triphenyl tin fluoride (TPTF) exposure.
RU2177028C1 (en) Composition for removal of organic and bacterial pollution
WO2004052358A1 (en) Urushiol induced contact dermatitis treatment and method of use
JPH0853339A (en) Dermal agent for external use
JP2007502289A (en) Compositions for the treatment of biting and invasive organisms, parasites and urticaria, and methods of use
US20050037039A1 (en) Composition for treatment of tinea pedis and method of use
JP2005527601A (en) Methods and compositions for inhibition of irritation by disaccharides and metal ions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/085 20060101AFI20070122BHEP

Ipc: A61P 17/10 20060101ALI20070122BHEP

Ipc: A61K 31/198 20060101ALI20070122BHEP

Ipc: A61K 45/06 20060101ALI20070122BHEP

17Q First examination report despatched

Effective date: 20070404

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WILLIAM M. YARBROUGH FOUNDATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WILLIAM M. YARBROUGH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070817